LIWANLI Innovation Co., Ltd. (TPE:3054)
46.00
-2.00 (-4.17%)
Jul 30, 2026, 11:04 AM CST
LIWANLI Innovation Revenue
LIWANLI Innovation had revenue of 203.44M TWD in the quarter ending June 30, 2026, with 537.36% growth. This brings the company's revenue in the last twelve months to 414.67M, up 355.60% year-over-year. In the year 2025, LIWANLI Innovation had annual revenue of 125.54M with 26.61% growth.
Revenue (ttm)
414.67M
Revenue Growth
+355.60%
P/S Ratio
9.34
Revenue / Employee
n/a
Employees
n/a
Market Cap
3.87B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 125.54M | 26.38M | 26.61% |
| Dec 31, 2024 | 99.16M | 60.27M | 154.98% |
| Dec 31, 2023 | 38.89M | 4.90M | 14.41% |
| Dec 31, 2022 | 33.99M | -13.83M | -28.91% |
| Dec 31, 2021 | 47.81M | -229.07M | -82.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Formosa Laboratories | 4.77B |
| Orient EuroPharma | 4.59B |
| Panion & Bf Biotech | 2.10B |
| Maywufa Company | 1.61B |
| Orient Pharma | 1.41B |
| SCI Pharmtech | 1.36B |
| Allied Biotech | 922.49M |
| Easywell Biomedicals | 682.56M |